Naloxegol - AstraZeneca

Drug Profile

Naloxegol - AstraZeneca

Alternative Names: AZ13337019 oxalate; MOVANTIK; Movantik; Moventig; Naloxegol oxalate; NKTR-118; NKTR-118 oxalate; Oral PEG-naloxol; Pegylated naloxol

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nektar Therapeutics
  • Developer AstraZeneca; Daiichi Sankyo Company; Knight Therapeutics; Nektar Therapeutics
  • Class Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Constipation(In adolescents, In children) in Spain (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Constipation(In adolescents, In children) in United Kingdom (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Constipation(In volunteers) in Japan (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top